Meeting
2011 ASCO Annual Meeting
A single-arm phase II trial evaluating docetaxel, vinorelbine, and GM-CSF in stage IV melanoma.
Authors
J. P. Fruehauf
UCI Comprehensive Cancer Center, Orange, CA
J. P. Fruehauf , Z. Eroglu , K. M. Kong , J. G. Jakowatz , W. L. Akerley , W. E. Samlowski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma
Clinical Trial Registration Number
NCT00256282
Citation
J Clin Oncol 29: 2011 (suppl; abstr 8546)
Abstract #
8546
Poster Bd #
25A
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A randomized phase 2 study of abemaciclib versus docetaxel in patients with stage IV squamous cell lung cancer (SqCLC) previously treated with platinum-based chemotherapy.
First Author: Giorgio V. Scagliotti
Poster
2012 ASCO Annual Meeting
A phase II, multicenter, open-label study of YM155 plus docetaxel in subjects with stage III (unresectable) or stage IV melanoma.
First Author: Joyce Leta Steinberg
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A modified triplet combination of docetaxel, oxaliplatin, and fluorouracil for gastric cancer (GC) with peritoneal carcinomatosis (PC) and inoperable malignant bowel obstruction (MBO): A multi-center, non-randomized, three-cohort, phase II trial (Zhen Jing).
First Author: Jian Xiao
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).
First Author: Izuma Nakayama